Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1

European Journal of Pharmacology
Cecilia NilssonAnette Sams

Abstract

The pharmacological potential of Calcitonin gene-related peptide (CGRP) beyond vasodilation is not completely understood and studies are limited by the potent vasodilatory effect and the short half-life of CGRP. In particular, the effects of CGRP on metabolic diseases are not clarified. A peptide analogue of the α form of CGRP (αAnalogue) with prolonged half-life (10.2 ± 0.9h) in rodents was synthesised and used to determine specific metabolic effects in 3 rodent models; normal rats, diet-induced obese rats and the Leptin deficient mouse model (ob/ob mice). The αAnalogue (100 nmol/kg) induced elevated energy expenditure and reduced food intake after single dosing in normal rats. In addition, the αAnalogue increased levels of circulating Glucagon-Like Peptide-1 (GLP-1) by >60% and a specific concentration dependent CGRP-induced GLP-1 secretion was verified in a murine L-cell line. Two weeks treatment of the type 2 diabetic ob/ob mice with the αAnalogue caused reduction in fasting insulin levels (199 ± 36 pM vs 332 ± 68 pM) and a tendency to reduce fasting blood glucose (11.2 ± 1.1mM vs 9.5 ± 0.5mM) and % glycosylated haemoglobin (HbA1c) (5.88 ± 0.17 vs 5.12 ± 0.24), demonstrating a potential anti-diabetic effect. Furthermore, tw...Continue Reading

References

Jan 3, 1985·Nature·S D BrainI MacIntyre
Sep 1, 1984·Peptides·D D KrahnJ E Morley
Dec 1, 1995·Trends in Pharmacological Sciences·D Poyner
Jan 30, 2007·Journal of Biomolecular Screening·Fritz Poulsen, Kirsten Borres Jensen
May 18, 2007·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·S BenemeiP Geppetti
May 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Lars Edvinsson, Tony W Ho
Jan 30, 2013·Biochemical Society Transactions·James BarwellDavid R Poyner
Oct 8, 2014·Physiological Reviews·F A RussellS D Brain
Apr 3, 2015·Physiological Reviews·Darleen A Sandoval, David A D'Alessio
Apr 19, 2015·Current Opinion in Neurology·Nazia Karsan, Peter J Goadsby
Aug 2, 2015·Bioorganic & Medicinal Chemistry Letters·Brendan M CrowleyChristopher S Burgey

❮ Previous
Next ❯

Citations

Jul 26, 2017·Circulation·A H Jan Danser, Antoinette MaassenVanDenBrink
Feb 23, 2020·International Journal of Molecular Sciences·Jing ZhuPaul Robert Hansen
Apr 11, 2020·Channels·Chenyang ZhangLihong Wang
Oct 25, 2016·ChemMedChem·Søren B van WitteloostuijnKnud J Jensen
Sep 9, 2017·Endocrine·William Gustavo LimaValéria Ernestânia Chaves
Oct 24, 2017·British Journal of Pharmacology·Debbie L HayChristopher S Walker
Jul 18, 2019·Frontiers in Physiology·Ambrish KumarDonald J DiPette
Mar 29, 2020·Headache·Athanasia Alexoudi, Spyros Deftereos
Mar 18, 2020·The Journal of Headache and Pain·Kristian Agmund HaanesAnette Sams
Mar 13, 2021·Trends in Endocrinology and Metabolism : TEM·Léa MontégutGuido Kroemer
Jun 6, 2021·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Simon BentsenRasmus S Ripa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.